Clinical Trial

Mesenchymal Stem Cells for Chronic Kidney Diseases

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Trial Details
NCT Number NCT07240987
Lead Sponsor The First Affiliated Hospital of Air Force Medicial University
Conditions Kidney Disease, Chronic, Diabetic Kidney Disease (DKD), Hypertensive Nephropathy
Enrollment 32 participants
Start Date 2026-01-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-24